Efficacy and Safety of Thai Herbal Formularies Benja Amarit in Hepatocellular Carcinoma Patients: Clinical Trial Phase II

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20170621002

Enrollment

Registered

2017-06-21

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This study to explore effficacy and safty of Thai herbal formularies Benja Amarit in hapatocellular carcinoma (Clinical trail phase II). Study in hepatocellular carcinoma patient&#44

Interventions

Active ingredientThai in Herbal Formularies Benja Amarit: 1. Piper retrofractum Vahl. 2. Zingiber officinale Roscoe. 3. Piper nigrum L. 4. Citrus hystrix DC. 5. Baliospermum montanum (Willd.) Muell

Experimental Drug,Placebo Comparator No treatment

Thai Herbal Formularies Benja Amarit,placebo

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who have been diagnosed is Hepatocellular carcinoma Child-Pugh score class A OR B. 2. Patients who cannot treat by standard treatment. 3. Stop another treatment not less than 4 weeks. 4. Stop radiation and chemotherapy not less than 4 weeks. 5. Thai, age between 18-80 years. 6. Zubrod-ECOG-WHO score between 0-2. 7. Patients who was evaluated to survival more than 5 months. 8. - To understand Thai language and to communicate with research assistants to assess side effects from treatment - Can receive medication and follow up as prescribed - Consent and sign the name in research

Exclusion criteria

Exclusion criteria: 1. Patients who have been allergy to ingredient of formularies Benja Amarit 2. Pregnant or breastfeeding women. 3. Receive chemotherapy or use herb or vitamin, its out of standard treatment. 4. Patient who have acute illness such as sepsis.

Design outcomes

Primary

Measure	Time frame
Overall survival day 0 28 56 84 112 140 Duration of survival	—

Secondary

Measure	Time frame
RECIST Criteria day 28 112 state of RECIST Criteria,Quality of life day 0 28 56 84 112 140 Thai Modified Function Living Index Cancer Questionnaire Version 2,safety day 0 28 56 84 112 140 Number of adverse drug event	—

Countries

Thailand

Contacts

Public ContactMonthaka Teerachaisakul

Thai Traditional Medicine Research Institute

monthaka.t@gmail.com02-224-3265

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026